Vimarsana
Biggest News Aggregation in the World

Peter Houweling News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Peter Houweling. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Peter Houweling Today - Breaking & Trending Today

Ivani's genetic disease is worsening as she ages. Her mother hopes Australia's new biobank will help | Health - Vimarsana News

Ivani's genetic disease is worsening as she ages. Her mother hopes Australia's new biobank will help | Health

Exclusive: National Muscle Disease Bio-databank will store blood test and skin biopsy samples from children with diseases such as muscular dystrophy

Dozens remain in Yellowknife hospital as evacuation stretches past deadline - Vimarsana News

Dozens remain in Yellowknife hospital as evacuation stretches past deadline

Over three dozen remain at The Stanton Territorial Hospital. NWT officials ordered Yellowknife residents to evacuate by Friday at noon.

Massive effort to protect Yellowknife continues as fire looms on horizon - Vimarsana News

Massive effort to protect Yellowknife continues as fire looms on horizon

A massive effort to protect Yellowknife, involving city and territorial workers, the military, and an army of local contractors, could be put to the test in the coming days as wildfire threatens to reach city limits.

Source: cbc.ca
New temporary day shelter opens in downtown Yellowknife - Vimarsana News

New temporary day shelter opens in downtown Yellowknife

After weeks of planning and construction, Yellowknife's new temporary day shelter opened Monday.

Source: cbc.ca
New collaboration between Antisense Therapeutics and MCRI - Vimarsana News

New collaboration between Antisense Therapeutics and MCRI

(ASX:ANP) has announced a new R&D collaboration with researchers at the Murdoch Children’s Research Institute’s (MCRI) to further investigate the potential of its ATL1102. The researchers, Dr Peter Houweling and Associate Professor Shireen Lamande, will investigate the potential of ATL1102 to deliver treatment for the control of immune-mediated inflammatory muscle damage in muscle diseases. The company said ATL1102 has been shown to be clinically active in Multiple Sclerosis and Duchenne muscular dystrophy (DMD) patients while antisense inhibition of CD49d has also previously demonstrate...